Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation - Poveda, A; Floquet, A; Ledermann, J A (J Clin Oncol, 2020)